Houston Biotechnology Inc
Business Identifier: NO Business Identifier is currently available for this company.
Public Profile:
in February 1997, Houston Biotechnology Incorporated was acquired by Medarex Inc, itself an SBIR-involved firm. Houston Biotechnology is primarily engaged in the research and development of biopharmaceutical products to treat or prevent certain eye diseases and conduct neurologic research in areas that are closely related to ophthalmology. The company's initial product, the 4197X-RA Immunotoxin, is currently in clinical testing for the prevention of secondary cataract, a common complication of primary extracapsular cataract surgery

 Synopsis: Awardee Business Condition
Year Founded IP Holdings
Employee Range VC funded?
Revenue Range Private/Public
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Drug Assocated Polymer Implants for Ocular Indications
Novel treatment for intractable pain
Disulfide linkage of immunotoxins by IGG oligosaccharide
Construction of chicken x mouse hybridomas
An Ocular Neurotrophic Factor to Treat Glaucoma